{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:18:54Z","timestamp":1793999934000,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluated the effectiveness and patient outcomes of a temporary switch from methadone to slow-release oral morphine (SROM) during COVID-19-related supply disruptions in Lithuania in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 231 patients at the Vilnius Branch of the Republican Centre for Addictive Disorders who received SROM for at least two days were retrospectively analyzed. The key metrics included methadone and SROM dosages, withdrawal severity (Clinical Opioid Withdrawal Scale (COWS)), and retention rates at 1, 3, 6, and 12 months post-switch. The data were compared by sex, methadone dosage group (low: 10\u201360\u00a0mg\/d, medium: 61\u2013100\u00a0mg\/d, high: 101\u2013150\u00a0mg\/d), and clinic attendance frequency. To contextualize long-term outcomes, retention rates were compared with annual program-level data from 2018 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients received SROM for an average of 8.4 days at an initial methadone-to-SROM ratio of 1:4, which increased to 1:5.23. Withdrawal symptoms were generally mild, peaking at a mean COWS score of 8.2. Women experienced more severe symptoms than men did. After two weeks of SROM therapy, methadone supplies were restored, and patients resumed their original treatment. The retention rates remained high at 1, 3, 6, and 12 months (97.8%, 96.1%, 93.5%, and 89.2%, respectively), with higher retention rates among patients with take-home doses, higher baseline methadone dosages, or longer treatment histories. Long-term program data confirmed that the temporary switch to SROM did not adversely affect overall treatment engagement compared with preceding and subsequent years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A temporary switch to SROM effectively managed methadone supply disruptions by serving as a viable substitute for methadone, causing minimal withdrawal symptoms and maintaining long-term retention. Coordinated clinical monitoring, institutional protocols, and supportive policy measures ensure continuity of care, emphasizing the value of flexible, personalized treatment strategies during crises.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00622-6","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:22:22Z","timestamp":1769048542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adapting opioid therapy: real-world analysis of switching from methadone to slow-release morphine and back amid COVID-19 supply chain disruptions"],"prefix":"10.1186","volume":"21","author":[{"given":"Art\u016bras","family":"Barkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilis","family":"Subata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Jakavi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Barkien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egl\u0117","family":"Lydekait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linas","family":"Zdanavi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giedrius","family":"Likatavi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Au\u0161ra","family":"\u0160irvinskien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaida","family":"Baltr\u016bnien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"622_CR1","unstructured":"EMCDDA trendspotter briefing - Impact of COVID-19 on drug services. and help-seeking in Europe | www.euda.europa.eu [Internet]. [cited 2025 Mar 4]. Available from: https:\/\/www.euda.europa.eu\/publications\/ad-hoc\/impact-of-covid-19-on-drug-services-and-help-seeking-in-europe_en"},{"key":"622_CR2","doi-asserted-by":"crossref","unstructured":"Joudrey PJ, Adams ZM, Bach P, Van Buren S, Chaiton JA, Ehrenfeld L, et al. Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada. JAMA Netw Open. 2021 July 1;4(7):e2118223.","DOI":"10.1001\/jamanetworkopen.2021.18223"},{"key":"622_CR3","doi-asserted-by":"crossref","unstructured":"Chen AY, Powell D, Stein BD. Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic. JAMA Netw Open. 2022 July 1;5(7):e2223708.","DOI":"10.1001\/jamanetworkopen.2022.23708"},{"key":"622_CR4","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.jsat.2021.108350","volume":"127","author":"K Lehmann","year":"2021","unstructured":"Lehmann K, Kuhn S, Baschirotto C, Jacobsen B, Walcher S, G\u00f6rne H, et al. Substitution treatment for opioid dependence with slow-release oral morphine: retention rate, health status, and substance use after switching to morphine. J Subst Abuse Treat. 2021;127:108350.","journal-title":"J Subst Abuse Treat"},{"key":"622_CR5","unstructured":"Opioid agonist treatment \u2013 the current situation in Europe. (European Drug Report 2024) | www.euda.europa.eu [Internet]. [cited 2024 Sept 29]. Available from: https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2024\/opioid-agonist-treatment_en"},{"key":"622_CR6","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.drugalcdep.2023.111036","volume":"254","author":"T Schwarz","year":"2024","unstructured":"Schwarz T, Anzenberger J, Busch M, Gmel G, Kraus L, Krausz M, et al. Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and Switzerland. Drug Alcohol Depend. 2024;254:111036.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"622_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/add.12440","volume":"109","author":"T Beck","year":"2014","unstructured":"Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014;109(4):617\u201326.","journal-title":"Addiction"},{"issue":"2","key":"622_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/JCP.0000000000000288","volume":"35","author":"L Falcato","year":"2015","unstructured":"Falcato L, Beck T, Reimer J, Verthein U. Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial. J Clin Psychopharmacol. 2015;35(2):150\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"622_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","volume":"47","author":"R H\u00e4mmig","year":"2014","unstructured":"H\u00e4mmig R, K\u00f6hler W, Bonorden-Kleij K, Weber B, Lebentrau K, Berthel T, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275\u201381.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"622_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/jcph.704","volume":"56","author":"P Glue","year":"2016","unstructured":"Glue P, Cape G, Tunnicliff D, Lockhart M, Lam F, Gray A, et al. Switching Opioid-Dependent patients from methadone to morphine: Safety, Tolerability, and methadone pharmacokinetics. J Clin Pharmacol. 2016;56(8):960\u20135.","journal-title":"J Clin Pharmacol"},{"key":"622_CR11","unstructured":"Goyer M\u00c8, Horman J, Plessis-B\u00e9lair MC, Schurter E. A Guide to Using Slow-Release Oral Morphine (Kadian\u00ae) in Opioid Agonist Therapy (OAT). Montr\u00e9al, Qc: CCSMTL. 2023;30."},{"issue":"8","key":"622_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1360-0443.2004.00764.x","volume":"99","author":"TB Mitchell","year":"2004","unstructured":"Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction. 2004;99(8):940\u20135.","journal-title":"Addiction"},{"issue":"8","key":"622_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","volume":"100","author":"H Eder","year":"2005","unstructured":"Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction. 2005;100(8):1101\u20139.","journal-title":"Addiction"},{"issue":"11","key":"622_CR14","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1360-0443.2008.02334.x","volume":"103","author":"A Kastelic","year":"2008","unstructured":"Kastelic A, Dubajic G, Strbad E. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction. 2008;103(11):1837\u201346.","journal-title":"Addiction"},{"key":"622_CR15","doi-asserted-by":"crossref","unstructured":"Bond AJ, Reed KD, Beavan P, Strang J. After the randomised injectable opiate treatment trial: post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. Drug Alcohol Rev. 2012 June;31(4):492\u20138.","DOI":"10.1111\/j.1465-3362.2011.00353.x"},{"key":"622_CR16","doi-asserted-by":"crossref","unstructured":"Baschirotto C, Lehmann K, Kuhn S, Reimer J, Verthein U. Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: analysis of the switching process in routine care. J Pharmacol Sci. 2020 Sept;144(1):9\u201315.","DOI":"10.1016\/j.jphs.2020.06.004"},{"key":"622_CR17","doi-asserted-by":"crossref","unstructured":"Ferri M, Minozzi S, Bo A, Amato L. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013 June;5(6):CD009879.","DOI":"10.1002\/14651858.CD009879.pub2"},{"key":"622_CR18","doi-asserted-by":"crossref","unstructured":"Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol. 2011 June;71(6):832\u201343.","DOI":"10.1111\/j.1365-2125.2011.03923.x"},{"issue":"4","key":"622_CR19","doi-asserted-by":"publisher","first-page":"e025799","DOI":"10.1136\/bmjopen-2018-025799","volume":"9","author":"J Klimas","year":"2019","unstructured":"Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Soc\u00edas ME, Fairbairn N, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9(4):e025799.","journal-title":"BMJ Open"},{"issue":"1","key":"622_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/YIC.0000000000000418","volume":"38","author":"J Giustiniani","year":"2023","unstructured":"Giustiniani J, Rothen S, Penzenstadler L, Colombo L, Calzada G, Thorens G, et al. Does slow release oral morphine have impact on craving and impulsivity in heroin dependent individuals? Int Clin Psychopharmacol. 2023;38(1):16\u201322.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"622_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/CXA.0000000000000072","volume":"10","author":"SM Ghosh","year":"2019","unstructured":"Ghosh SM, Klaire S, Tanguay R, Manek M, Azar P. A review of novel methods to support the transition from methadone and other full agonist opioids to Buprenorphine\/Naloxone Sublingual in both community and acute care settings. Can J Addict. 2019;10(4):41.","journal-title":"Can J Addict"},{"key":"622_CR22","unstructured":"The jamovi project [Internet]. jamovi. 2022 [cited 2024 Dec 1]. Available from: https:\/\/www.jamovi.org\/"},{"issue":"1","key":"622_CR23","doi-asserted-by":"publisher","first-page":"2094111","DOI":"10.1080\/17482631.2022.2094111","volume":"17","author":"C Russell","year":"2022","unstructured":"Russell C, Pang M, Nafeh F, Farrell Macdonald S, Derkzen D, Rehm J, et al. Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. Int J Qual Stud Health Well-being. 2022;17(1):2094111.","journal-title":"Int J Qual Stud Health Well-being"},{"issue":"5","key":"622_CR24","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: A systematic review. PLoS ONE. 2020;15(5):e0232086.","journal-title":"PLoS ONE"},{"issue":"1","key":"622_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","volume":"10","author":"J Klimas","year":"2021","unstructured":"Klimas J, Hamilton MA, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10(1):216.","journal-title":"Syst Rev"},{"key":"622_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2018.08.024","volume":"193","author":"S Amiri","year":"2018","unstructured":"Amiri S, Hirchak K, Lutz R, McDonell MG, McPherson SM, Roll JM, et al. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. Drug Alcohol Depend. 2018;193:63\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"622_CR27","doi-asserted-by":"crossref","unstructured":"Mitchell TB, White JM, Somogyi AA, Bochner F. Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. American J Addict. 2006 July 8;15(4):311\u20135.","DOI":"10.1080\/10550490600754374"},{"key":"622_CR28","volume-title":"Recommendations for use of slow-release oral morphine as opioid agonist therapy","author":"K Cheema","year":"2023","unstructured":"Cheema K, Kahan M, Rodgers J, Smoke A. Recommendations for use of slow-release oral morphine as opioid agonist therapy. Toronto, ON: META:PHI; 2023."},{"key":"622_CR29","unstructured":"British Columbia Centre on Substance Use BM of H, BC Ministry of Mental Health and Addictions. A Guideline for the Clinical Management of Opioid Use Disorder [Internet]. British Columbia Centre on Substance Use. 2023. Available from: https:\/\/www.bccsu.ca\/opioid-use-disorder\/"},{"issue":"2","key":"622_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cpdd.326","volume":"6","author":"ED Kharasch","year":"2017","unstructured":"Kharasch ED. Current concepts in methadone metabolism and transport. Clin Pharmacol Drug Dev. 2017;6(2):125\u201334.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"622_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1526-4637.2008.00461.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9(5):595\u2013612.","journal-title":"Pain Med"},{"key":"622_CR32","doi-asserted-by":"crossref","unstructured":"Leppert W. The role of methadone in cancer pain treatment\u2013a review. Int J Clin Pract. 2009 July;63(7):1095\u2013109.","DOI":"10.1111\/j.1742-1241.2008.01990.x"},{"issue":"8","key":"622_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40263-020-00743-3","volume":"34","author":"D Kreutzwiser","year":"2020","unstructured":"Kreutzwiser D, Tawfic QA. Methadone for pain management: A pharmacotherapeutic review. CNS Drugs. 2020;34(8):827\u201339.","journal-title":"CNS Drugs"},{"issue":"6","key":"622_CR34","first-page":"479","volume":"8","author":"M Kloke","year":"2000","unstructured":"Kloke M, Rapp M, Bosse B, Kloke O. Toxicity and\/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer. 2000;8(6):479\u201386.","journal-title":"Support Care Cancer"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00622-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:22:31Z","timestamp":1769048551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-025-00622-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00622-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}